List view / Grid view
9 July 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Dalfampridine Extended-release Tablets, 10 mg...
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
9 July 2014 | By Boehringer Ingelheim
Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...
9 July 2014 | By
Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer. 1,2 It predominantly affects people over 60 and is one of the most common adult leukaemias in the Western World.1 The current standard of care is intensive chemotherapy, but many older patients cannot tolerate this therapeutic approach; their…
8 July 2014 | By kdm communications
Tecan has introduced an innovative new consumable device offering increased throughput and capacity for Freedom EVO® workstations...
8 July 2014 | By Novartis
Novartis released new global guidelines for Investigator Initiated Trials...
8 July 2014 | By Sanofi
Sanofi announced that the U.S. Food and Drug Administration has accepted for review the company’s New Drug Application for Toujeo®...
7 July 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza® (daclatasvir)...
7 July 2014 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Judit Makara from the Institute of Experimental Medicine of the Hungarian Academy of Sciences in Budapest, Hungary...
4 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases...
4 July 2014 | By Roche
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib...
4 July 2014 | By Daiichi Sankyo
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo Co., Ltd., announced that Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2 inhibitor, CANAGLU® tablets 100mg (generic name: canagliflozin hydrate, hereafter, CANAGLU®) in Japan, for the treatment of patients with type 2 diabetes mellitus...
4 July 2014 | By Teva
An extended regimen oral contraceptive that provides quarterly menses – a new concept for women in Europe...
3 July 2014 | By Department of Health
The Prime Minister David Cameron called for global action to tackle the growing threat of resistance to antibiotics...
3 July 2014 | By Public Health England
PHE and other stakeholders providing technical support to the affected countries...
